neurocare group AG announces publication in Biological Psychiatry CNNI revealing first clinically actionable EEG biomarker in ADHD



MUNICH, May 06, 2022 (GLOBE NEWSWIRE) — neurocare group AG (“neurocare” or the “Company”), a leading innovator in personalized mental health and performance empowering clinicians to deliver best practices , announced the publication of one of the largest EEG (electroencephalogram, a test that measures electrical signals/activity in the brain) biomarker studies to date in the journal Biological Psychiatry CNNI. The article, “Brainmarker-I Differentially Predicts Remission to Various Treatments of Attention Deficit/Hyperactivity Disorder: A Discovery, Crossover, and Blinded Validation Study”, validates Brainmarker-I as the first biomarker Clinically usable EEG.

In this study, the authors, including Rosalinde van Ruth of Neurocare and her scientific advisor Martijn Arns, studied a specific biomarker, Brainmarker-I, to help find the best possible treatment for patients with attention disorders / hyperactivity (ADHD). The study focused on stratifying treatment into two common interventions for ADHD, Ritalin and Neurofeedback. Brainmarker-I reliably showed which treatment the patient responds preferentially to and thus a 29-36% higher remission of symptoms could be achieved.

“The study further validates the importance of our integrated approach of providing personalized therapy to achieve the best possible and longest-lasting outcomes for patients with mental health conditions such as ADHD,” said Tom Mechtersheimer, founder and CEO of neurocare. “We are excited to bring Brainmarker-I to market as part of our unique digital therapy platform enabling clinicians to deliver best practices by integrating technology, software and services. The results of the study confirm our recognition that the treatment needs of each patient are different. The rigor and robustness of this study aligns with our highly scientific approach to provide the best clinical outcomes with superior efficacy and outcomes.”

Brainmarker-I was developed in a large heterogeneous clinical sample (TD-BRAIN+: N=4249). The researchers first tested its ability to stratify between Ritalin and Neurofeedback on two other large data sets (Ritalin treatment (N=336) and Brainclinics/neurocare Neurofeedback treatment data (N=136)). Next, the researchers performed blinded, out-of-sample validations in two independent datasets, in which the results were successfully replicated and implicated a 29-36% improvement in remission. Additionally, the link between Brainmarker-I and remission to the drugs Guanfacine and Atomoxetine has been investigated.

Helena Voetterl, lead author and researcher at the Brainclinics Research Institute, comments: “This study highlights the benefits and the need for more international collaboration and data sharing, showing that the whole is superior to the sum of its parts. The collaboration between the institutions not only allowed access to a wide range of data from individuals with diverse symptom profiles, but also allowed us to capitalize on pre-existing expertise.”

Researchers from the following institutions collaborated in this study: neurocare group AG; the nonprofit Brainclinics Foundation; Maastricht University, Amsterdam UMC, University of Amsterdam; Brain Dynamics Centre, University of Sydney; Brain Resource Ltd.; the University of North Carolina at Asheville; University of California, Los Angeles (UCLA); Radboud University of Nijmegen; Ohio State University; EEG Resource Institute; Neuroscan and Eindhovens Psychologisch Instituut.

The full publication in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging can be viewed here.

About neurocare group AG:
neurocare innovates in mental health and performance. We offer the first Digital Therapy Platform (DTP) in its field that enables clinicians to deliver best practices. Our integrated and personalized therapeutic approach is based on a solid experience in clinical sciences with more than 20 years of research and technological development. Our business is driven by two strong growth channels: building our own clinics and supplying our unique DTP to third parties. We currently treat around 2,000 patients a year in our own clinics.

Pamela Keck
neurocare group AG
[email protected]

This content was posted through the press release distribution service on


Comments are closed.